|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US6222020B1
(en)
|
1987-01-07 |
2001-04-24 |
Imperial Cancer Research Technology Limited |
Antigens derived from the core protein of the human mammary epithelial mucin
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
DE3851889T2
(de)
|
1987-06-24 |
1995-04-13 |
Florey Howard Inst |
Nukleosid-derivate.
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69126530T2
(de)
|
1990-07-27 |
1998-02-05 |
Isis Pharmaceutical, Inc., Carlsbad, Calif. |
Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
CA2155762C
(en)
|
1994-08-23 |
2000-04-25 |
Haruya Sato |
Protein modification method
|
|
US6017700A
(en)
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
EP2112225A1
(en)
|
1996-07-25 |
2009-10-28 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
EP1012276A2
(en)
|
1997-02-24 |
2000-06-28 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against muc1 tumor-associated antigen
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
EP1151299A4
(en)
|
1999-01-22 |
2003-06-04 |
Smithkline Beecham Corp |
PROCESS OF LOCATION-SPECIFIC MARKING OF PROTEINS AND APPLICATIONS
|
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
|
WO2001097843A2
(en)
|
2000-06-22 |
2001-12-27 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
|
EP1641481A4
(en)
|
2003-05-30 |
2008-10-15 |
Centocor Inc |
TRAINING OF NEW ERYTHROPOIETIN CONJUGATES USING TRANSGLUTAMINASE
|
|
US20070184537A1
(en)
|
2003-06-03 |
2007-08-09 |
Paul Scherrer Institut |
Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides
|
|
ES2343965T3
(es)
|
2003-11-25 |
2010-08-13 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Anticuerpos anti-cd22 e inmunocongujados mutados.
|
|
US20070105770A1
(en)
|
2004-01-21 |
2007-05-10 |
Novo Nordisk A/S |
Transglutaminase mediated conjugation of peptides
|
|
ES2642214T3
(es)
|
2004-01-21 |
2017-11-15 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
|
JP4931798B2
(ja)
|
2004-03-15 |
2012-05-16 |
ケイ．アール． カラオリス，デイヴィッド |
免疫、炎症または神経保護応答のための方法
|
|
CA2586913A1
(en)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
WO2007140371A2
(en)
|
2006-05-30 |
2007-12-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
SI2056845T1
(en)
|
2006-08-08 |
2018-02-28 |
Rheinische Friedrich-Wilhelms-Universitaet Bonn |
STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
|
|
CN101517082B
(zh)
|
2006-09-27 |
2014-01-22 |
科勒制药有限责任公司 |
具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
|
|
PT2170353E
(pt)
*
|
2007-05-18 |
2015-09-16 |
Adiutide Pharmaceuticals Gmbh |
Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante
|
|
KR101811965B1
(ko)
|
2007-11-07 |
2017-12-22 |
셀덱스 쎄라퓨틱스, 인크. |
인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
WO2010002042A1
(ja)
|
2008-07-04 |
2010-01-07 |
国立大学法人 九州大学 |
タンパク質ラベル化用酵素基質
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
WO2011108682A1
(ja)
|
2010-03-05 |
2011-09-09 |
国立大学法人 東京大学 |
リボヌクレオシドホスホロチオエートの製造方法
|
|
US8450293B2
(en)
|
2010-08-10 |
2013-05-28 |
Rutgers, The State University Of New Jersey |
Synthesis and characterization of C8 analogs of c-di-GMP
|
|
CA2930801C
(en)
|
2010-11-05 |
2019-05-28 |
Rinat Neuroscience Corporation |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
|
GB201021867D0
(en)
|
2010-12-23 |
2011-02-02 |
Mologen Ag |
Non-coding immunomodulatory DNA construct
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2013016278A2
(en)
|
2011-07-22 |
2013-01-31 |
Children's Medical Center Corporation |
Modulators of antiviral signaling pathways and therapeutic uses thereof
|
|
AP2014007595A0
(en)
|
2011-09-30 |
2014-04-30 |
Kineta Inc |
Anti-viral compounds
|
|
US8871908B2
(en)
|
2011-11-11 |
2014-10-28 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
EP2596806A1
(en)
|
2011-11-25 |
2013-05-29 |
Index Pharmaceuticals AB |
Method for prevention of colectomy
|
|
AU2012356894B2
(en)
|
2011-12-23 |
2018-01-18 |
Araris Biotech Ltd. |
Enzymatic conjugation of polypeptides
|
|
EA034778B1
(ru)
|
2012-02-06 |
2020-03-19 |
Инхибркс, Инк. |
Антитела к cd47 и способы их применения
|
|
WO2013163162A1
(en)
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
EP2869847B1
(en)
|
2012-07-09 |
2017-12-06 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
|
DK2872485T3
(da)
|
2012-07-13 |
2021-03-08 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
JP6246121B2
(ja)
|
2012-07-13 |
2017-12-13 |
株式会社新日本科学 |
キラル核酸アジュバント
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
JP6578206B2
(ja)
|
2012-07-19 |
2019-09-18 |
レッドウッド バイオサイエンス， インコーポレイテッド |
Ｃｄ２２に特異的な抗体およびその使用方法
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
EA201590396A1
(ru)
|
2012-12-13 |
2015-12-30 |
Адуро Биотек, Инк. |
Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
|
|
WO2014124433A1
(en)
*
|
2013-02-11 |
2014-08-14 |
Oregon Health & Science University |
5'-triphosphate oligoribonucleotides
|
|
WO2014140300A1
(en)
|
2013-03-15 |
2014-09-18 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
ES2982836T3
(es)
|
2013-04-29 |
2024-10-17 |
Memorial Sloan Kettering Cancer Center |
Composiciones y métodos para alterar la señalización de segundos mensajeros
|
|
EP2992000B1
(en)
|
2013-05-03 |
2020-07-08 |
The Regents of The University of California |
Cyclic di-nucleotide induction of type i interferon
|
|
EP3974520A1
(en)
*
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
ME03586B
(me)
|
2013-05-18 |
2020-07-20 |
Univ California |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
CN111437395A
(zh)
|
2013-08-29 |
2020-07-24 |
希望之城 |
细胞穿透缀合物及其使用方法
|
|
JP2016537027A
(ja)
*
|
2013-11-06 |
2016-12-01 |
ソルスティス バイオロジクス，リミティッド |
ジスルフィド基を有するポリヌクレオチド構築物
|
|
WO2015073746A2
(en)
|
2013-11-13 |
2015-05-21 |
Whitehead Institute For Biomedical Research |
18f labeling of proteins using sortases
|
|
EP3071209A4
(en)
|
2013-11-19 |
2017-08-16 |
The University of Chicago |
Use of sting agonist as cancer treatment
|
|
WO2015097267A1
(en)
|
2013-12-23 |
2015-07-02 |
Covalab |
mTG SUBSTRATES FOR COVALENT CONJUGATION OF COMPOUNDS
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
WO2015172099A1
(en)
|
2014-05-09 |
2015-11-12 |
Kineta, Inc. |
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
EP3152308A4
(en)
|
2014-06-06 |
2017-12-27 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having bioreversible and non-bioreversible groups
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
MX388181B
(es)
|
2014-07-22 |
2025-03-19 |
Cb Therapeutics Inc |
Anticuerpos anti-pd-1.
|
|
US20180134802A1
(en)
|
2016-01-08 |
2018-05-17 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
JP6762030B2
(ja)
|
2014-11-20 |
2020-09-30 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
|
|
EP3229836B1
(en)
*
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
ES2764178T3
(es)
|
2014-12-16 |
2020-06-02 |
Kayla Therapeutics |
Dinucleótidos cíclicos fluorados para inducción de citocinas
|
|
US10815481B2
(en)
|
2014-12-16 |
2020-10-27 |
Roche Innovation Center Copenhagen A/S |
Chiral library screen
|
|
CA2971246C
(en)
|
2014-12-19 |
2020-07-14 |
F. Hoffmann-La Roche Ag |
Identification of transglutaminase substrates and uses therefor
|
|
WO2016109415A1
(en)
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
WO2016205042A1
(en)
|
2015-06-16 |
2016-12-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRPα AGONIST ANTIBODY
|
|
WO2017011444A1
(en)
|
2015-07-13 |
2017-01-19 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating b cell cancers
|
|
WO2017011622A1
(en)
|
2015-07-14 |
2017-01-19 |
Spring Bank Pharmaceuticals, Inc. |
Compounds and compositions that induce rig-i-and other pattern recongnition receptors
|
|
KR102085968B1
(ko)
|
2015-07-20 |
2020-03-06 |
조에티스 서비시즈 엘엘씨 |
리포솜 보조제 조성물
|
|
AU2016298227B9
(en)
|
2015-07-30 |
2019-10-31 |
Macrogenics, Inc. |
PD-1-binding molecules and methods of use thereof
|
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
|
WO2017049251A2
(en)
|
2015-09-18 |
2017-03-23 |
Tioma Therapeutics, Inc. |
Therapeutic cd47 antibodies
|
|
HK1257309A1
(zh)
|
2015-09-21 |
2019-10-18 |
Erasmus University Medical Center |
抗-cd47抗体及使用方法
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
WO2017100461A1
(en)
*
|
2015-12-08 |
2017-06-15 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
|
|
JP2019513692A
(ja)
|
2016-02-19 |
2019-05-30 |
ジェニスフィア・エルエルシー |
核酸キャリア及び治療上の使用方法
|
|
KR20220143151A
(ko)
|
2016-04-01 |
2022-10-24 |
바이셀릭스, 인크. |
신규 rna 구축물 및 세포독성 세포 및 줄기 세포의 치료 효과를 증진시키기 위한 그의 사용 방법
|
|
EP3443010B1
(en)
|
2016-04-14 |
2024-08-07 |
Ose Immunotherapeutics |
New anti-sirpa antibodies and their therapeutic applications
|
|
TW201741340A
(zh)
|
2016-05-09 |
2017-12-01 |
賽基公司 |
Cd47抗體及使用其之方法
|
|
DK3455257T3
(da)
|
2016-05-09 |
2021-11-01 |
Igm Biosciences Inc |
Anti-pd-l1-antistoffer
|
|
CN109414500B
(zh)
|
2016-06-13 |
2022-02-25 |
奥美药业有限公司 |
治疗和诊断用pd-l1特异性单克隆抗体
|
|
US10059769B2
(en)
|
2016-06-13 |
2018-08-28 |
I-Mab |
Anti-PD-L1 antibodies and uses thereof
|
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
KR102878970B1
(ko)
|
2016-08-03 |
2025-10-30 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
CN110325549B
(zh)
|
2016-12-09 |
2024-03-08 |
艾利妥 |
抗SIRPα抗体及其使用方法
|
|
KR102808275B1
(ko)
*
|
2017-04-14 |
2025-05-20 |
탈락 테라퓨틱스, 인크. |
면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
|
|
US12458705B2
(en)
|
2018-06-12 |
2025-11-04 |
Angiex, Inc. |
Antibody-oligonucleotide conjugates
|
|
BR112021007294A2
(pt)
|
2018-10-17 |
2021-07-27 |
Tallac Therapeutics, Inc. |
imunomodulação de conjugados de polinucleotídeos e métodos de uso
|
|
US11920136B2
(en)
|
2020-02-28 |
2024-03-05 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
|
WO2022040173A1
(en)
|
2020-08-18 |
2022-02-24 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|